<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159713">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01847794</url>
  </required_header>
  <id_info>
    <org_study_id>CGOG5002</org_study_id>
    <nct_id>NCT01847794</nct_id>
  </id_info>
  <brief_title>HER2 Positive CTC in Advanced Gastric Cancer</brief_title>
  <acronym>AGC-HER2CTC</acronym>
  <official_title>Clinical Significance of HER2 Positive Circulating Tumor Cells(CTCs) in the Peripheral Blood of Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify the correlation of HER2 expression in tissue and peripheral CTC. to identify the
      HER2 expression in CTCs with clinical prognosis in advanced/metastatic gastric cancer.

      Confirm the presence of CTCs are sensitive for monitoring response to chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>HER2 positive CTC</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical significance of HER 2 positive CTC</measure>
    <time_frame>2years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HER2 Positive Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>chemotheropy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cell Search® CTC epithelial kit</intervention_name>
    <description>Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).
Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.
Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.</description>
    <arm_group_label>chemotheropy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having signed informed consent

          -  Age≥ 18 years old

          -  HER2 overexpression confirmed by IHC or ISH (IHC 3+,or IHC2+/ISH+)

          -  Histologically confirmed gastric adenocarcinoma

          -  Unresectable recurrent or metastatic disease

          -  Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more
             than 6 months

          -  Measurable disease according to the RECIST criteria

          -  Karnofsky performance status ≥70

          -  Life expectancy of ≥3 month

          -  No prior radiotherapy except radiotherapy at non-target lesion of the study more than
             4 weeks

          -  ALT and AST&lt;2.5 times ULN (≤5 times ULN in patients with liver metastases)

          -  Serum albumin level ≥3.0g/dL

          -  Serum AKP &lt; 2.5 times ULN

          -  Serum creatinine &lt;ULN, and CCr &lt; 60ml/min

          -  Bilirubin level &lt; 1.5 ULN

          -  WBC&gt;3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet&gt;100,000/mm3, Hb&gt;9g/dl

        Exclusion Criteria:

          -  Previous systemic therapy for metastatic gastric cancer

          -  Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry
             Contraindications of nuclear magnetic resonance image such as fitment of cardiac
             pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball
             and so on.

          -  Allergic constitution or allergic history to protium biologic product or any
             investigating agents.

          -  Severe heart disease or such history as recorded congestive heart failure,
             uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve
             disease, severe abnormal ECG findings, cardiac infarction , or retractable
             hypertension.

          -  Pregnancy or lactation period

          -  Other previous malignancy within 5 year, except non-melanoma skin cancer

          -  Legal incapacity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lin shen, MD. PhD</last_name>
    <phone>(86)10-88196175</phone>
    <email>lin100@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking cancer hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xiaotian zhang, MD. PhD</last_name>
      <phone>(86)10-88196561</phone>
      <email>zhangxtxx@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>jifang gong, MD. PhD</last_name>
      <phone>(86)10-88196561</phone>
      <email>gongjifang@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 2, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Director of GI oncology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
